{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:15:41Z","timestamp":1791256541383,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00366-x","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T05:04:55Z","timestamp":1752901495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with\u00a0tyrosine kinase inhibitors"],"prefix":"10.1186","volume":"11","author":[{"given":"Naoki","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Tabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mitsumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"366_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/onco.13944","volume":"26","author":"MT Chen","year":"2021","unstructured":"Chen MT, Huang ST, Lin CW, Ko BS, Chen WJ, Huang HH, Hsiao FY. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based. Propensity Score-Matched Cohort Study Oncologist. 2021;26:974\u201382. https:\/\/doi.org\/10.1002\/onco.13944.","journal-title":"Propensity Score-Matched Cohort Study Oncologist"},{"key":"366_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","volume":"97","author":"I Fujioka","year":"2018","unstructured":"Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018;97:2081\u20138. https:\/\/doi.org\/10.1007\/s00277-018-3412-8.","journal-title":"Ann Hematol"},{"key":"366_CR3","doi-asserted-by":"publisher","unstructured":"Okumura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb. 2024;31:641\u2013853. https:\/\/doi.org\/10.5551\/jat.GL2022.","DOI":"10.5551\/jat.GL2022"},{"key":"366_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/aje\/kwn064","volume":"167","author":"N Rumana","year":"2008","unstructured":"Rumana N, Kita Y, Turin TC, Murakami Y, Sugihara H, Morita Y, Tomioka N, Okayama A, Nakamura Y, Abbott RD, et al. Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990\u20132001. Am J Epidemiol. 2008;167:1358\u201364. https:\/\/doi.org\/10.1093\/aje\/kwn064.","journal-title":"Am J Epidemiol"},{"key":"366_CR5","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1161\/STROKEAHA.110.581033","volume":"41","author":"TC Turin","year":"2010","unstructured":"Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M, Sugihara H, Morita Y, Hirose K, Okayama A, et al. Ischemic stroke subtypes in a Japanese population: Takashima Stroke Registry, 1988\u20132004. Stroke. 2010;41:1871\u20136. https:\/\/doi.org\/10.1161\/STROKEAHA.110.581033.","journal-title":"Stroke"},{"key":"366_CR6","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.cir.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837\u201347. https:\/\/doi.org\/10.1161\/01.cir.97.18.1837.","journal-title":"Circulation"},{"key":"366_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635\u2013701. https:\/\/doi.org\/10.1093\/eurheartj\/ehs092.","journal-title":"Eur Heart J"},{"key":"366_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.5551\/jat.61960","volume":"29","author":"T Honda","year":"2022","unstructured":"Honda T, Chen S, Hata J, Yoshida D, Hirakawa Y, Furuta Y, Shibata M, Sakata S, Kitazono T, Ninomiya T. Development and Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Disease in Japanese Adults: The Hisayama Study. J Atheroscler Thromb. 2022;29:345\u201361. https:\/\/doi.org\/10.5551\/jat.61960.","journal-title":"J Atheroscler Thromb"},{"key":"366_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"366_CR10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"366_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2337\/diacare.2.2.120","volume":"2","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120\u20136. https:\/\/doi.org\/10.2337\/diacare.2.2.120.","journal-title":"Diabetes Care"},{"key":"366_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1161\/01.cir.99.9.1165","volume":"99","author":"P Jousilahti","year":"1999","unstructured":"Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99:1165\u201372. https:\/\/doi.org\/10.1161\/01.cir.99.9.1165.","journal-title":"Circulation"},{"key":"366_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.7326\/0003-4819-87-4-393","volume":"87","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study Ann Intern Med. 1977;87:393\u20137. https:\/\/doi.org\/10.7326\/0003-4819-87-4-393.","journal-title":"The Framingham study Ann Intern Med"},{"key":"366_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/archinte.167.11.1122","volume":"167","author":"PA McCullough","year":"2007","unstructured":"McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167:1122\u20139. https:\/\/doi.org\/10.1001\/archinte.167.11.1122.","journal-title":"Arch Intern Med"},{"key":"366_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hon.2617","volume":"37","author":"N Iriyama","year":"2019","unstructured":"Iriyama N, Tokuhira M, Sato E, Sugimoto KJ, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, et al. Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis. Hematol Oncol. 2019;37:323\u20135. https:\/\/doi.org\/10.1002\/hon.2617.","journal-title":"Hematol Oncol"},{"key":"366_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12032-018-1093-8","volume":"35","author":"M Tokuhira","year":"2018","unstructured":"Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, et al. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol. 2018;35:38. https:\/\/doi.org\/10.1007\/s12032-018-1093-8.","journal-title":"Med Oncol"},{"key":"366_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354. https:\/\/doi.org\/10.1038\/leu.2016.5.","journal-title":"Leukemia"},{"key":"366_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2.","journal-title":"Lancet Oncol"},{"key":"366_CR19","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1182\/bloodadvances.2018020396","volume":"2","author":"S Gopal","year":"2018","unstructured":"Gopal S, Lu Q, Man JJ, Baur W, Rao SP, Litichevskiy L, Papanastasiou M, Creech AL, DeRuff KC, Mullahoo J, et al. A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML. Blood Adv. 2018;2:1680\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2018020396.","journal-title":"Blood Adv"},{"key":"366_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","volume":"60","author":"A Gover-Proaktor","year":"2019","unstructured":"Gover-Proaktor A, Granot G, Pasmanik-Chor M, Pasvolsky O, Shapira S, Raz O, Raanani P, Leader A. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma. 2019;60:189\u201399. https:\/\/doi.org\/10.1080\/10428194.2018.1466294.","journal-title":"Leuk Lymphoma"},{"key":"366_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294438","volume":"18","author":"Y Wang","year":"2023","unstructured":"Wang Y, Travers RJ, Farrell A, Lu Q, Bays JL, Stepanian A, Chen C, Jaffe IZ. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors. PLoS ONE. 2023;18: e0294438. https:\/\/doi.org\/10.1371\/journal.pone.0294438.","journal-title":"PLoS ONE"},{"key":"366_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40959-023-00164-3","volume":"9","author":"T Kaneko","year":"2023","unstructured":"Kaneko T, Miyazaki S, Kurita A, Morimoto R, Tsuchiya S, Watanabe N, Takaku T, Komatsu N, Minamino T. Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study. Cardiooncology. 2023;9:11. https:\/\/doi.org\/10.1186\/s40959-023-00164-3.","journal-title":"Cardiooncology"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00366-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T05:04:56Z","timestamp":1752901496000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00366-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00366-x","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board: This study was approved by the Ethics Committee of Juntendo University School of Medicine (H20-0088).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"TTak received speaker honoraria from Novartis Pharma K.K. and research funds from Bristol-Myers Squibb and Otsuka Pharmaceutical. NI received speaker honoraria from Bristol-Myers Squibb, Novartis Pharma K.K, Otsuka Pharmaceutical, and Pfizer Inc. EI received speaker honoraria from Bristol-Myers Squibb, Novartis Pharma K.K. and Otsuka Pharmaceutical. TTab received speaker honorarium from Jansen Pharmaceutical and scholarship funds from Chugai Pharmaceutical. MT received speaker honoraria from Bristol-Myers Squibb, Chugai Pharmaceutical, Novartis Pharma K.K., and Sanofi K.K. KM received a speaker honorarium from Novartis Pharma K.K., Bristol-Myers Squibb and Otsuka Pharmaceutical. TK received a speaker honorarium from Alexion Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}